Notably, the phase 2randomized LIXIPARK trial assessed lixisenatide—a GLP-1 receptor agonisttypically prescribed for type 2 diabetes—as a possible disease-modifyingintervention in early-stage PD. Here, GLP1R is linked to Parkinson disease.